Alzahouri: Cost-effectiveness analysis of strategies introducing FDG-PET into the
mediastinal staging of non-small-cell lung cancer from the French healthcare system
perspective. Clinical Radiology (2005) 60, 479–492
The AMCP Format for Formulary Submissions Ver 21. April 2005
The Format and other formulary submission guidelines support the informed selection
of pharmaceuticals, biologics and vaccines by: Standardizing and communicating
product and supporting program information requirements;
Arrive´: A Scale of Methodological Quality for Clinical Studies of Radiologic
Examinations. Radiology 2000; 217:69–74
Cleemput: Methodology for calculating a country’s need for positron emission
tomography scanners. Internat J Technol Assess in Health Care, 24:1 (2008), 20–24.
Primer on Cost-Effectiveness Analysis
Czernin: Improvements in Cancer Staging with PET/CT: Literature-Based Evidence as
of September 2006. J Nucl Med 2007; 48:78S–88S
Facey: Overview of the clinical effectiveness of positron emission tomography imaging
in selected cancers. Health Technology Assessment 2007; Vol. 11: No. 44
Fleming: Impact of FDG PET/CTon Previously Untreated Head and Neck Cancer
Patients. Laryngoscope, 117:1173–1179, 2007
Fryback: The Efficacy of Diagnostic Imaging. Med Decis Making 1991;11:88- 94
Garden: Guidelines for resection of colorectal cancer liver metastases. Gut 2006;55;1-8
Gazelle: Cost-effectiveness Analysis in the Assessment of Diagnostic Imaging
Technologies. Radiology 2005; 235:361–370
Hastings: Joint project of the international network of agencies for health
technology assessment—Part 1: Survey results on diffusion, assessment, and clinical use
of positron emission tomography. Internat J Technol Assess in Health Care, 22:2 (2006),
143–148.
Kielar: Health-Related Quality of Life and Cost-Effectiveness Analysis in Radiology.
Acad Radiol 2007; 14:411–419
Krug: Is a methodology available that accurately measures the cost of an FDG-PET
study? Eur J Nucl Med Mol Imaging (2007) 34:625–627
Krupinski: Anniversary Paper: Evaluation of medical imaging systems. Med. Phys. 35
(2), February 2008 pp645-659
The authors review the hierarchical model of the efficacy of diagnostic imaging
systems by Fryback and Thornbury
Kwee: Imaging in staging of malignant lymphoma: a systematic review. Blood.
2008;111:504-516
Lejeune: Use of a Decision Analysis Model to Assess the Cost-Effectiveness of 18FFDG PET in the Management of Metachronous Liver Metastases of Colorectal Cancer. J
Nucl Med 2005; 46:2020–2028
Merhige: Impact of Myocardial Perfusion Imaging with PET and 82Rb on Downstream
Invasive Procedure Utilization, Costs, and Outcomes in Coronary Disease Management. J
Nucl Med 2007; 48:1069–1076
Muller: Overview of Economic Evaluation of Positron-Emission Tomography. The
European Journal of Health Economics, Vol. 3, No. 1. (2002), pp. 59-65.
Murray: Development of WHO guidelines on generalized cost-effectiveness analysis.
Health Econ. 9: 235–251 (2000)
Nandalur: Diagnostic performance of positron emission tomography in the detection of
coronary artery disease: a meta-analysis. Acad Radiol. 2008 Apr;15(4):444-51
Podoloff: NCCN Task Force Report: PET/CT Scanning in Cancer. JNCCN 2007;
5(Suppl 1):S1–S22
PET SCAN PRIMER: A Guide to the Implementation of Positron Emission Tomography
Imaging in Ontario August 31, 2008
Park: Decision Analysis for the Cost-Effective Management of Recurrent Colorectal
Cancer. ANNALS OF SURGERY Vol. 233, No. 3, 310–319. 2001
Pelosi. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET)
in the management of patients with colorectal cancer: A Review. Eur J Surg Oncol. 2007
Feb;33(1):1-6.
Sheehan: FDG PET in Preoperative Assessment of Colorectal Liver Metastases
Combining “Evidence-Based Practice” and “Technology Assessment” Methods to
Develop Departmental Imaging Protocols: Should FDG PET Be Routinely Used in the
Preoperative Assessment of Patients With Colorectal Liver Metastases? Acad Radiol
2007; 14:389–397
Singer: Cost-Effectiveness Analysis in Radiology. Radiology 2001; 219:611–620
SSAT: Society for Surgery of the Alimentary Tract - Patient Care Guidelines: Surgery
for Hepatic Colorectal Metastases. Approved May 15, 2004
The STARD checklist for reporting information in diagnostic accuracy studies
STARD Flowchart
Streiner: Diagnosing Tests: Using and Misusing Diagnostic and Screening Tests.
JOURNAL OF PERSONALITY ASSESSMENT, 81(3), 209–219
Strobel: Cost-effective therapy remission assessment in lymphoma patients using FDG
PET/CT: is an end of treatment exam necessary in all patients? Annals of Oncology 18:
658–664, 2007
van Hooren: The cost-effectiveness of (18)FDG-PET in selecting patients with suspicion
of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch
Otorhinolaryngol. 2008 Nov 29
Walker: How to do (or not to do). . . Cost and cost-effectiveness guidelines: which ones
to use? HEALTH POLICY AND PLANNING 2001; 16(1): 113–121
Yap: Positron emission tomography with selected mediastinoscopy compared to routine
mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of
non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2005) 32:1033–1040
Yen: The Cost-utility Analysis of FDG PET in the Diagnosis of Recurrent
Nasopharyngeal Carcinoma. Acad Radiol. 2009 Jan;16(1):54-60.
Zubeldia: The Economic Impact of 18FDG Positron Emission Tomography in the
Surgical Management of Colorectal Cancer with Hepatic Metastases. Ca Biotherapy &
Radiopharm. Volume 20, Number 4, 2005. pp 450-456.